ZENAS BIOPHARMA INC (ZBIO) Forecast, Price Target & Analyst Ratings
NASDAQ:ZBIO • US98937L1052
25.28 USD
+0.02 (+0.08%)
At close: Mar 6, 2026
25.28 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ZENAS BIOPHARMA INC (ZBIO).
Forecast Snapshot
Consensus Price Target
$41.57
+ 64.42% Upside
Next Earnings Forecast
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$1.05
Revenue Estimate39.1M
ChartMill Buy Consensus
87.14%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$41.57
Upside
+ 64.42%
From current price of $25.28 to mean target of $41.57, Based on 14 analyst forecasts
Low
$19.19
Median
$45.39
High
$57.75
Price Target Revisions
1 Month
0.00%
3 Months
-6.48%
Price Target Summary
14 analysts have analysed ZBIO and the average price target is 41.57 USD. This implies a price increase of 64.42% is expected in the next year compared to the current price of 25.28.
The average price target has been revised downward by 6.48% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.14%
ZBIO was analyzed by 14 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about ZBIO.
In the previous month the buy percentage consensus was at a similar level.
ZBIO was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-06 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-12-22 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-11-26 | Evercore ISI Group | Initiate | Outperform |
| 2025-11-13 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-28 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-28 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-09 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-20 | Wedbush | Initiate | Outperform |
| 2025-03-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-04 | Wolfe Research | Initiate | Outperform |
| 2024-12-16 | HC Wainwright & Co. | Initiate | Buy |
| 2024-12-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-12-03 | Guggenheim | Reiterate | Buy |
| 2024-10-08 | Guggenheim | Initiate | Buy |
| 2024-10-08 | Morgan Stanley | Initiate | Overweight |
| 2024-10-08 | Citigroup | Initiate | Buy |
| 2024-10-08 | Jefferies | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$1.05
Revenue Estimate39.1M
Revenue Q2Q682.00%
EPS Q2Q73.72%
Number of Analysts8
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-39.47%
EPS (1 Month)
0.00%
EPS (3 Months)
-117.80%
Next Earnings Summary
ZBIO is expected to report earnings on 3/9/2026. The consensus EPS estimate for the next earnings is -1.05 USD and the consensus revenue estimate is 39.10M USD.
The next earnings revenue estimate has been revised downward by 39.47% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 50M | 5M -90.00% | 29.75M 495.00% | -100.00% | 52.712M | 140.89M 167.28% | 272.25M 93.24% | 460.5M 69.15% | 741.59M 61.04% | 952.23M 28.40% | 1.157B 21.50% | ||
| EBITDA YoY % growth | -75.121M | -27.034M 64.01% | -163.751M -505.72% | -207.551M -26.75% | -253.34M -22.06% | -276.486M -9.14% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -75.199M | -27.147M 63.90% | -163.888M -503.71% | -178.827M -9.12% | -258.6M -44.61% | -263.814M -2.02% | -267.556M -1.42% | -181.063M 32.33% | -54.218M 70.06% | 141.62M 361.21% | 336.61M 137.69% | 492.78M 46.39% | |
| Operating Margin | N/A | -54.29% | -3,277.76% | -601.10% | N/A | -500.48% | -189.90% | -66.51% | -11.77% | 19.10% | 35.35% | 42.59% | |
| EPS YoY % growth | N/A | N/A | N/A | -4.15 44.46% | -4.65 -12.10% | -4.44 4.46% | -3.14 29.28% | -2.09 33.44% | 0.10 104.63% | 2.58 2,557.89% | 2.36 -8.51% | 4.03 71.00% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.05 73.72% | -1.20 -49.43% | -1.10 12.32% | -1.10 9.87% | -0.79 25.10% | -1.27 -6.06% | 2.33 312.56% | -1.23 -12.06% | -1.23 -55.97% |
| Revenue Q2Q % growth | 39.1M 682.00% | -100.00% | 36.142M -7.57% | 1.624M | 76.5M | 1.679M | 5.454M -84.91% | ||
| EBITDA Q2Q % growth | -55.102M 0.69% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -38.84M 30.17% | -60.377M -61.74% | -61.585M -11.64% | -62.816M -32.02% | -19.192M 50.59% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.01%
EPS Next 5 Year
10.94%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-22.68%
EBIT Next 5 Year
N/A
ZENAS BIOPHARMA INC / ZBIO Forecast FAQ
What is the price target for ZBIO stock?
14 analysts have analysed ZBIO and the average price target is 41.57 USD. This implies a price increase of 64.42% is expected in the next year compared to the current price of 25.28.
When does ZENAS BIOPHARMA INC (ZBIO) report earnings?
ZENAS BIOPHARMA INC (ZBIO) will report earnings on 2026-03-09.
What are the consensus estimates for ZENAS BIOPHARMA INC (ZBIO) next earnings?
The consensus EPS estimate for the next earnings of ZENAS BIOPHARMA INC (ZBIO) is -1.05 USD and the consensus revenue estimate is 39.10M USD.